Pfizer Reports Phase 2 Results for 25-Valent Pediatric Vaccine Candidate
Pfizer announced detailed serotype results from a Phase 2 study of investigational vaccine candidate PF-07872412 in infants. A four-dose series elicited immune responses, according to the company.